Sen. Gillibrand Says U.S. Generics Need Incentives to Reshore; Cost Shouldn’t Trump Quality

Sen. Gillibrand Says U.S. Generics Need Incentives to Reshore; Cost Shouldn’t Trump Quality

It’s the second month in a row now that the U.S. Senate Special Committee on Aging has taken up the question of our woeful generic drugs supply chain. This time, however, Ranking Member  Kirsten Gillibrand (D-NY), started the hearing off by touching on a key topic in pharmaceuticals: the cost equation can no longer override the quality equation.“There is one framing that is repeated at each of these hearings, and that is that the United States h…